Prime Medicine, Inc. (PRME) — Analyst outlook / Analyst consensus target is. Based on 9 analyst ratings, the consensus is bullish — 5 Buy, 4 Hold.
The consensus price target is $17.25 (low: $12.00, high: $23.00), representing an upside of 366.2% from the current price $3.70.
Analysts estimate Earnings Per Share (EPS) of $-1.60 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.65 vs est $-1.60 (missed -3.1%). 2025: actual $-1.35 vs est $-1.32 (missed -2.1%). Analyst accuracy: 97%.
PRME Stock — 12-Month Price Forecast
$17.25
▲ +366.22% Upside
Average Price Target
Based on 9 Wall Street analysts offering 12-month price targets for Prime Medicine, Inc., the average price target is $17.25, with a high forecast of $23.00, and a low forecast of $12.00.
The average price target represents a +366.22% change from the last price of $3.70.
Highest Price Target
$23.00
Average Price Target
$17.25
Lowest Price Target
$12.00
PRME Analyst Ratings
Buy
Based on 9 analysts giving stock ratings to Prime Medicine, Inc. in the past 3 months
EPS Estimates — PRME
97%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$1.65
vs Est –$1.60
▼ 3.0% off
2025
Actual –$1.35
vs Est –$1.32
▼ 2.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — PRME
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.003B
vs Est $0.012B
▼ 287.2% off
2025
Actual $0.005B
vs Est $0.005B
▼ 7.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast significant revenue growth ahead.
